Wave Life Sciences, Inc. (WVE) Fair Value 2026

WVE · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (41/100)

Quick Summary — As of 2026-08-28, Wave Life Sciences, Inc. (WVE) trades at $5.04. QOC: 6.6/10. Value Trap Risk: 41/100 (WARN). 0/13 models active.

Key Facts

Ticker
WVE
Price
$5.04
Quality Score
6.6/10
Value Trap Risk
41/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 41 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give WVE?

0 Intrinsic Value Models vs. Current Price ($5.04)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Wave Life Sciences, Inc. (WVE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Wave Life Sciences, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About WVE?

0 of 13 models are currently active for WVE. See which stocks rank higher →

How Does WVE Rank in Biotechnology?

Among 625 Biotechnology stocks, WVE ranks #77 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Wave Life Sciences, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is WVE a Value Trap?

CirclFi's Value Trap algorithm assigns WVE a score of 41/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Wave Life Sciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Wave Life Sciences, Inc. scores 6.6 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every WVE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Wave Life Sciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ABCLAbCellera Biologics Inc.QOC 6.6NTRBNutriband Inc.QOC 6.6ZYMEZymeworks Inc.QOC 6.6ACRSAclaris Therapeutics, Inc.QOC 6.6MRKRMarker Therapeutics, Inc.QOC 6.7AXSMAxsome Therapeutics, Inc.QOC 6.6IMMPImmutep LimitedQOC 5.4BNTCBenitec Biopharma Inc.QOC 4.7MBRXMoleculin Biotech, Inc.QOC 3.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ABCL · NTRB · ZYME · ACRS · MRKR · AXSM · IMMP · BNTC · MBRX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to WVE?

7 companies across all industries closest to WVE’s Quality of Company score of 6.6/10.

RNWReNew Energy Global PlcQOC 6.6WBDWarner Bros. Discovery, Inc.QOC 6.6BMTMBright Mountain Media, Inc.QOC 6.6NPCENeuroPace, Inc.QOC 6.6ODYSOdysight.ai Inc.QOC 6.6EOSEEos Energy Enterprises, Inc.QOC 6.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RNW · WBD · BMTM · NPCE · ODYS · EOSE · NVDA

Where Does WVE Sit in CirclFi's Biotechnology Rankings?

WVE is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Wave Life Sciences, Inc.’s Valuation?

What is Wave Life Sciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Wave Life Sciences, Inc. (WVE). The Quality of Company score is 6.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is WVE overvalued or undervalued right now?

At $5.04, 0 of 0 active models suggest WVE may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Wave Life Sciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.6 mean for WVE?

Wave Life Sciences, Inc.'s QOC of 6.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on WVE?

CirclFi analyzes WVE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is WVE a value trap in 2026?

Wave Life Sciences, Inc.'s Value Trap score is 41/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Wave Life Sciences, Inc. (WVE) a Quality of Company score of 6.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/WVE/ · Methodology
Primary sources for this WVE valuation
  • Financial statements: Wave Life Sciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001631574) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for WVE as of ; valuations recomputed .